Guangdong Institute of Translational Medicine for Innovative Drugs

Guangdong Institute of Innovative Drugs (GDID) is a specialized research and development organization located in the Guangzhou International Bio Island, China. Established in 2018 as a "New R&D Institution," it serves as a critical bridge between basic academic research and industrial drug application. The institute focuses on high-impact therapeutic areas such as oncology, metabolic diseases, and autoimmune disorders, utilizing advanced platforms for small molecule discovery, biologics, and translational medicine. GDID's pipeline includes several promising candidates, most notably GDI-101, a novel USP7 inhibitor currently in early clinical development for solid tumors. The institute maintains strong strategic partnerships with leading academic centers like the Shanghai Institute of Materia Medica and provides comprehensive CRO and translational services to the regional biotechnology sector. By integrating research, incubation, and technical services, GDID plays a pivotal role in the biopharmaceutical innovation ecosystem of the Guangdong-Hong Kong-Macao Greater Bay Area.